Exhibit 10.34 VITAL LIVING, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT This Scientific Advisory Board Agreement ("Agreement") dated May 7, 2002, (the "Effective Date") is made by and between Vital Living, Inc., a Nevada corporation, whose address is...Scientific Advisory Board Agreement • April 28th, 2003 • Vital Living Inc • Pharmaceutical preparations • California
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 24th, 2000 • Keryx Biophamaeuticals Inc • Services-commercial physical & biological research • New York
Scientific Advisory Board AgreementScientific Advisory Board Agreement • September 15th, 2023 • Acesis Holdings Corp. • Biological products, (no disgnostic substances) • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as January 1, 2023 (the “Effective Date”), and is entered into by Acesis Biomed US, Inc., with a business address at 9233 Park Meadows Drive Suite 108, Lone Tree, Colorado 80124, USA (the “Company”), and Dr. Ravi Kacker with a business address at 67 Union St #308, Natick, Massachusetts 01760 (the “Advisor”). This Agreement shall replace and supersede any and all previous written agreements between the Company and Advisor regarding Scientific Advisory Board Services.
EX-10.25 24 b67189a2exv10w25.htm EX-10.25 SCIENTIFIC ADVISORY BOARD AGREEMENT, (TARIQ RANA, PH.D.)Scientific Advisory Board Agreement • May 5th, 2020 • Delaware
Exhibit 10.25 EXECUTION COPY RXI PHARMACEUTICALS CORPORATION SCIENTIFIC ADVISORY BOARD AGREEMENT This Scientific Advisory Board Agreement (the “Agreement”) dated as of February 26, 2007, is made by Tariq M. Rana, Ph.D. (the “SAB Member”) and RXi Pharmaceuticals Corporation, a Delaware corporation (“RXi” and together with the SAB Member, the “Parties”). The SAB Member is a faculty member at the University of Massachusetts. AGREEMENT 1. General. (A) Effective Date. Subject to the terms and conditions of this Agreement, this Agreement will become effective upon the completion of all the following events:
AGREEMENT BY AND BETWEEN SYBLEU INC. INC. AND DR. JASON E. GARBERScientific Advisory Board Agreement • November 3rd, 2020 • SYBLEU Inc • Pharmaceutical preparations • California
Agreement made on July 7,2020 (“Execution Date”) by and between Dr. Jason E. Garber (“Scientific Advisory Board Member” also referred to as “SAB Member”), a natural person whose address is at 3012 South Durango, Las Vegas NV and SYBLEU INC. Inc. (“Company”), a Wyoming corporation whose principal office address is 4700 Spring Street, Suite 304, La Mesa CA 91942. SAB Member and Company may be referred to individually as “Party” and collectively as “Parties”.
Exhibit 10.12 Scientific Advisory Board Agreement with Jason MooreScientific Advisory Board Agreement • April 4th, 2002 • Genomed Inc
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 5th, 2010 • Medgenics, Inc. • New York
THIS AGREEMENT (the “Agreement”) dated as of 22 October 2008 (“Effective Date”) is made by and between Medgenics, Inc. located at 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182, USA (the “Company”); and
Scientific Advisory Board AgreementScientific Advisory Board Agreement • March 7th, 2018 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of March 1, 2018 (the “Effective Date”), and is entered into by IASO BioMed Inc., with a business address at 7315 East Peakview Ave., Centennial, CO 80111, USA (the “Company”), and Dr. Costas Karatzas personally or through CNKonsulting with a business address at _____________________________ (the “Advisor”).
MICROLIN BIO, INC. Scientific Advisory Board AgreementScientific Advisory Board Agreement • December 22nd, 2015 • American Boarding Co • Real estate • New York
This Scientific Advisory Board Agreement (the “Agreement”) is made and entered into as of December 18, 2013 (the “Effective Date”), by and between Microlin Bio, Inc., a Delaware company, having its principal place of business at 302A W. 12th Street, NY, NY 10014 (the “Company”), and Dr. George Calin, an individual with an address at 1515 Holcombe Blvd., Unit 1950, Houston, TX 77030-4009 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
AGREEMENTScientific Advisory Board Agreement • May 17th, 2004 • Cytrx Corp • Biological products, (no disgnostic substances) • Delaware
STOKE THERAPEUTICS, INC. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • August 8th, 2022 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This SCIENTIFIC ADVISORY BOARD Agreement (this “Agreement”) is entered into as of June 1, 2022 (the “Effective Date”) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (“Stoke”) and Adrian Krainer, Ph.D. (“Advisor”). Advisor has unique skills and knowledge pertinent to Stoke’s business and Stoke desires to retain Advisor as a member of Stoke’s Scientific Advisory Board (“SAB”) under the terms of this Agreement.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • June 10th, 2015 • E-Qure Corp. • Wholesale-misc durable goods • California
THIS ADVISORY BOARD AGREEMENT is made effective as of January 1, 2015, (the "Effective Date") by and between E-QURE Corp, a (the "Company"), and Dr. Ben Zion Weiner (the "Advisor").
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 11th, 2011 • Stem Cell Assurance, Inc. • Services-misc health & allied services, nec • Florida
SCIENTIFIC ADVISORY BOARD AGREEMENT, dated as of June 10, 2011, by and between NAIYER IMAM, M.D. (the “Advisor”), having an address at 6185 Steeplechase Drive, Roanoke, Virginia, and STEM CELL ASSURANCE, INC., a Nevada corporation (the “Company”), having offices at 555 Heritage Drive, Suite 130, Jupiter, Florida 33458.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California
This Scientific Advisory Board Agreement (“Agreement”), effective as of June 18, 2012 (“Effective Date”), is made between Caribou Biosciences, Inc. (“Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”) (each may be referred to below individually as a “party” and collectively as the “parties”).
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California
This [***] Scientific Advisory Board Agreement (this “Agreement”) is made and entered into as of January 1, 2017 (the “Effective Date”), and is by and between Caribou Biosciences, Inc., a Delaware corporation, and Jennifer A. Doudna, an individual (“Advisor”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).
MICROLIN BIO, INC. Scientific Advisory Board AgreementScientific Advisory Board Agreement • December 22nd, 2015 • American Boarding Co • Real estate • New York
This Scientific Advisory Board Agreement (the “Agreement”) is made and entered into as of September 18, 2013 (the “Effective Date”), by and between MicroLin Bio, Inc., a Delaware company, having its principal place of business at 302A W. 12th Street, NY, NY 10014 (the “Company”), and Dr. Philip Tsichlis, an individual with an address at 25 Jefferson Road, Winchester MA, 01890 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
Amendment No. 5 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 5 to Scientific Advisory Board Agreement (“Amendment No. 5”), effective January 1, 2020 (“Amendment No. 5 Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016, Amendment No. 3 to Scientific Advisory Board Agreement, dated January 1, 2017, and Amendment No. 4 to Scientific Advisory Board Agreement, dated March 31, 2018 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used in this Amendment No. 5 that is not defined herein has the meaning ascribed to it in the Agreement.
MICROLIN BIO, INC. Scientific Advisory Board AgreementScientific Advisory Board Agreement • December 22nd, 2015 • American Boarding Co • Real estate • New York
This Scientific Advisory Board Agreement (the “Agreement”) is made and entered into as of December 19, 2013 (the “Effective Date”), by and between MicroLin Bio, Inc., a Delaware company, having its principal place of business at 302A W. 12th Street, NY, NY 10014 (the “Company”), and Dr. Sakari Kauppinen, an individual with an address at Norskekrogen 12, DK-2765 Smoerum, Denmark (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
Amendment No. 3 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3, effective January 1, 2017 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, and Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined has the meaning ascribed to it in the SAB Agreement.
Amendment No. 2 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2, effective May 31, 2016 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated April 12, 2014 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation having its address at 2929 7th Street, Suite 105, Berkeley, CA 94710, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined shall have the meaning ascribed to it in the SAB Agreement.
ERASCA, INC. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • June 25th, 2021 • Erasca, Inc. • Pharmaceutical preparations • California
THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2020 (the “Effective Date”), by and between ERASCA, INC., a Delaware corporation (the “Company”), having its principal place of business at 10835 Road to the Cure, Suite 140, San Diego, CA 92121, and MICHAEL D. VARNEY, PH.D., an individual with an address at 709 N. Granados Ave., Solana Beach, CA 92075 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
MICROLIN BIO, INC. Scientific Advisory Board AgreementScientific Advisory Board Agreement • December 22nd, 2015 • American Boarding Co • Real estate • New York
This Scientific Advisory Board Agreement (the “Agreement”) is made and entered into as of September 20, 2013 (the “Effective Date”), by and between MicroLin Bio, Inc., a Delaware company, having its principal place of business at 302A W. 12th Street, NY, NY 10014 (the “Company”), and Dr. Robert Lee, an individual with an address at 2300 Green Island Dr., Columbus, OH 43228 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND MOHAMMAD HARIS, PH.D.Scientific Advisory Board Agreement • January 19th, 2023 • Regen BioPharma Inc • Pharmaceutical preparations
Agreement made on November 22, 2022, by and between MOHAMMAD HARIS (“Scientific Advisory Board Member” also referred to as ”SAB Member ”), a natural person whose address is___________, and Regen BioPharma, Inc. (“Company”), a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. SAB Member and Company may be referred to individually as “Party” and collectively as “Parties”.
Amendment No. 4 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 4, effective March 31, 2018 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016, and Amendment No. 3 to Scientific Advisory Board Agreement, dated January 1, 2017 (“Amendment No. 3”) (and collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined has the meaning ascribed to it in the SAB Agreement.
AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California
This Amendment No. 1 (“Amendment No. 1”) to the Scientific Advisory Board Agreement dated June 18, 2012 (the “Agreement”), by and between Jennifer A. Doudna (“Advisor”), an individual, and Caribou Biosciences, Inc., a Delaware corporation, having its principal place of business at 2929 7th Street Suite 120, Berkeley, CA 94710 (“Caribou”) (Advisor and Caribou collectively referred to hereinafter as the “Parties”), is entered into as of April 12, 2014 (the “Amendment No. 1 Execution Date”).
MICROLIN BIO, INC. Scientific Advisory Board AgreementScientific Advisory Board Agreement • January 10th, 2014 • Microlin Bio, Inc. • New York
This Scientific Advisory Board Agreement (the “Agreement”) is made and entered into as of August 7, 2013 (the “Effective Date”), by and between MicroLin Bio, Inc., a Delaware company, having its principal place of business at 302A W. 12th Street, NY, NY 10014 (the “Company”), and Dr. Carlo Croce, an individual with an address at 2104 Cambridge Blvd, Columbus, OH 43221 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • February 16th, 2010 • Lifevantage Corp • Pharmaceutical preparations • California
This Scientific Advisory Board Agreement (“Agreement”) is by and between Joe McCord, M.D., (“Consultant”) and LifeVantage Corporation (the “Company”), effective as of October 1, 2009, the (“Effective Date”). Company and Consultant may be referred to herein individually as a “Party” and together as the “Parties.”
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 5th, 2010 • Medgenics, Inc. • New York
THIS AGREEMENT (the “Agreement”) dated as of May 1 2006 (“Effective Date”) is made by and between Medgenics, Inc. located at of 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182. USA (the “Company”); and
AMENDMENT OF SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • September 28th, 2011 • Lifevantage Corp • Pharmaceutical preparations
This Amendment of the Scientific Advisory Board Agreement (“Amendment”) is made and entered into as of July 21, 2011 (“Execution Date”) by and between Dr. Joe M. McCord, Ph.D., (“Consultant”) and LifeVantage Corporation, a Colorado Corporation (the “Company”).
FORM OF SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • May 14th, 2007 • Modigene Inc. • Services-mailing, reproduction, commercial art & photography • New York
This Agreement is made as of _____________ ___, 2005, between Modigene Inc. (the "Company"), and ____________________ (the "Consultant"'), and shall be effective as of the date this Agreement has been approved by the Board of Directors of the Company (the "Effective Date"). Consultant has been involved in fields of particular interest to the Company. The Company wishes to retain Consultant in a consulting capacity as a member of the Company's Scientific Advisory Board (the "SAB"), and Consultant desires to perform such consulting services. Accordingly, the parties agree as follows:
Letter Agreement - Scientific Advisory Board InNexus April 17, 2007Scientific Advisory Board Agreement • December 26th, 2007 • Innexus Biotechnology Inc • Pharmaceutical preparations
As we have discussed, I ask for you to serve as a member of InNexus' Scientific Advisory Board. I am delighted in your interest and below, I have detailed the terms of your service. As a member of the Scientific Advisory Board, I expect you to provide your best advice and recommendations regarding InNexus' antibody technology. providing a peer review function and giving me your best effort in this regard. The Scientific Advisory Board will not be directly responsible for research, publication of research results, participation in research studies, validation of scientific studies, or compilation of data or information. Rather, you serve to advise.
BRIGHT MINDS BIOSCIENCES LTD. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • June 17th, 2021 • Bright Minds Biosciences Inc. • New York
THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (the "Agreement") is made and entered into as of 25 September 2019 (the "Effective Date"), by and between Bright Minds Biosciences Ltd., 1055 W Georgia St #1500, Vancouver, BC V6E 4N7 (the "Company"), and Jianmin Duan, with an address at "****" (the "Advisor"). The Company and the Advisor may be referred to herein individually as "Party" or collectively, as "Parties."
INVIVO THERAPEUTICS CORPORATION SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 1st, 2010 • Invivo Therapeutics Holdings Corp. • Wholesale-furniture & home furnishings • Massachusetts
This Scientific Advisory Board Agreement (this “Agreement”) between [insert name], having an address at [insert address] (the “Member”), and InVivo Therapeutics Corporation, (the “Company”), a Delaware corporation having a principal place of business at One Broadway 14th Floor, Cambridge, MA 02142, is made effective as of September 25, 2008 (the “Effective Date”). In connection with the appointment of the Member to the Advisory Board (the “SAB”) of the Company and the mutual promises of the parties hereunder, it is agreed as follows:
Scientific Advisory Board AgreementScientific Advisory Board Agreement • September 15th, 2023 • Acesis Holdings Corp. • Biological products, (no disgnostic substances) • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of January 1, 2023 (the “Effective Date”), and is entered into by Acesis Biomed US, Inc., with a business address at 9233 Park Meadows Drive - Suite 108, Lone Tree, Colorado 80124, USA (the “Company”), and Peter Yiwen Liu, MD, PhD with a business address 1124 W Carson St Bldg RB1, Torrance, California 90502 (the “Advisor”). This Agreement shall replace and supersede any and all previous written agreements between the Company and Advisor regarding Scientific Advisory Board Services.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • March 21st, 2014 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Arizona
THIS AGREEMENT (the “Agreement”) is made and entered into this 24th day of December, 2013 (the “Effective Date”) between Lixte Biotechnology Holdings, Inc., 248 Route 25A No. 2, East Setauket, New York 11733 (hereinafter referred to as the “Company”), and NDA Consulting Corp., an Arizona corporation, with offices at 9977 N. 90th Street, Suite 175, Scottsdale, Arizona 85258 (hereinafter referred to as the “Consultant”).
